Drug Trial Radar · NCT00897949
MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,473
Actual
Start
Mar 1995
Primary completion
Jan 1996
Study completion Jul 1996
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo. The long term extension study which pools patients from MK0462-022, -025, and -029 is described in NCT01286207.
Conditions
- Migraine Headache
Interventions
rizatriptan benzoate (MK0462)Drug
Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
Comparator: placeboDrug
Placebo to rizatriptan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain Relief at 2 Hours After the Initial Dose of Test DrugTime frame: 2 hours after initial dose of test drug
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.